Solventum Stock Down Despite Q4 Earnings & Revenues Beat, Margins Down

Core Insights - Solventum (SOLV) reported Q4 2025 adjusted EPS of $1.57, exceeding the Zacks Consensus Estimate of $1.50 by 4.7%, and showing an 11.3% year-over-year improvement [1] - The company achieved revenues of $1.99 billion, a 3.7% increase from the previous year, and beat the Zacks Consensus Estimate by 1.6% [2] Revenue Details - Revenue growth was driven by all segments, particularly the Infection Prevention and Surgical Solutions business within MedSurg and Dental Solutions [2] - Organic sales growth was reported at 3.5%, with shares down 2.5% in after-hours trading on Feb. 26 [2] Segmental Performance - MedSurg: Revenues reached $1.24 billion, up 5.2% reportedly and 3.2% organically year-over-year, driven by NPWT and V.A.C. Peel and Place Dressings [3] - Dental Solutions: Revenues totaled $343 million, an 8.6% increase year-over-year, supported by strong performance in core restoratives and recent product launches [4] - Health Information Systems (HIS): Revenues amounted to $348 million, up 3.7% reportedly and 3.2% organically, driven by the adoption of 360 Encompass revenue cycle management [4] Margins and Expenses - Adjusted gross profit was $1.07 billion, down 8.3% year-over-year, with an adjusted gross margin of 53.5%, a decrease of approximately 270 bps [5] - Selling, general and administrative expenses were $759 million, down 3.2% year-over-year, while research and development expenses totaled $175 million, down 12.1% [5] Financial Position - Solventum ended Q4 with cash, cash equivalents, and investments of $8.78 million, a decrease from $1.64 billion in the previous quarter [8] - Total assets increased to $14.29 billion from $13.97 billion in the previous quarter [8] 2026 Guidance - The company expects organic sales growth at the higher end of 2-3%, with adjusted EPS projected between $6.40 and $6.60 [9] - The Zacks Consensus Estimate for earnings is $6.36 per share [9] Strategic Initiatives - Solventum completed its acquisition of Acera Surgical, expanding its MedSurg portfolio, and launched a "Transform for the Future" initiative aimed at delivering approximately $500 million in annual cost savings [11] - Progress on separation from 3M is ahead of plan, with improvements in service levels and operational control [12]